

**IN THE UNITED STATES DISTRICT COURT  
FOR THE EASTERN DISTRICT OF PENNSYLVANIA**

<b>IN RE: GLUGAGON-LIKE</b>	:	<b>CIVIL ACTION</b>
<b>PEPTIDE-1 RECEPTOR AGONISTS</b>	:	
<b>(GLP-1 RAS) PRODUCTS</b>	:	
<b>LIABILITY LITIGATION</b>	:	
<hr style="width: 30%; margin-left: 0;"/>	:	<b>MDL No. 3094</b>
	:	<b>24-md-3094</b>
<b>THIS DOCUMENT RELATES TO:</b>	:	
	:	<b>HON. KAREN SPENCER MARSTON</b>
<b><i>ALL ACTIONS/ALL CASES</i></b>	:	
<hr style="width: 30%; margin-left: 0;"/>		

**CASE MANAGEMENT ORDER NO. 12**

**PLAINTIFF FACT SHEETS**

**AND NOW**, this 12th day of July, 2024, upon consideration of the parties’ Joint Motion for the Entry of Proposed Case Management Order (Doc. No. 173), it is **ORDERED** that the motion is **GRANTED** as follows.

**I. SCOPE OF ORDER**

This Order applies to all Plaintiffs and their counsel in: (1) all actions transferred to *In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation* (“MDL 3094”) by the Judicial Panel on Multidistrict Litigation (“JPML”) pursuant to its Order of February 2, 2024; (2) all related actions originally filed in or removed to this Court; and (3) any “tag-along” actions transferred to this Court by the JPML pursuant to Rules 6.2 and 7.1 of the Rules of Procedure of the JPML, subsequent to the filing of the final transfer order by the Clerk of this Court (collectively, “Member Actions”). The obligation to provide a Plaintiff Fact Sheet (“PFS”) and related documents shall fall solely to Plaintiffs and the individual counsel of record representing a given Plaintiff under this Order.

## **II. PLAINTIFF FACT SHEETS**

### **A. The PFS Form**

The form PFS that shall be used in MDL 3094 and all Member Actions is attached hereto as **Exhibit A**. In accordance with the schedule set forth below, every Plaintiff in each Member Action shall:

1. Complete and execute a PFS, which includes completion of Section VI “Documents and Things”;
2. Produce executed authorizations to obtain discoverable records, using the form authorizations using the form authorizations attached to the parties’ motion (Doc. No. 173) as Exhibits B through Q (Doc. Nos. 173-13 to 173-18) (or as modified as required by any medical provider or receiving party); and
3. Serve the completed and executed PFS, as well as all documents requested, upon counsel for each Defendant named in the Member Action.

### **B. Record Collection**

The parties to this litigation hereby agree to jointly use Medical Records Consultants (“MRC”) to collect for the parties the medical and other records from third parties in this action. Plaintiff(s) agree to provide the agreed-upon releases to MRC, and any party may request that MRC obtain records from a custodian by so advising MRC. Once records are obtained, MRC shall then make records available to all parties on an equal basis (including the use of the same pricing for all parties) and shall satisfy any obligation of a party obtaining records through MRC to make such records available to other parties. To the extent any provider requires a release other than the agreed-upon release, Plaintiffs shall complete reasonable requests for provider-specific authorization form within a reasonable amount of time. All communications with MRC regarding the collection of medical records in cases in this litigation shall copy the individual case counsel for the opposing party. The parties further agree that the release of documents to Defendants shall

not constitute a waiver of privilege, legal protection, or right to seek a clawback of inadvertently released documents.

Plaintiffs not seeking economic damages shall not be required to sign an authorization for the release of their employment records. Plaintiffs not pursuing claims for emotional distress shall certify they are not pursuing claims for emotional distress and, if such certification is completed, shall not be required to sign an authorization for the release of mental health records. Signing an authorization for release of mental health treatment records shall not constitute waiver of any claim of privilege or any other legal protection for such records under applicable law. Any authorization provided by Plaintiff shall become null and void when his or her case is resolved, and any use of the authorizations beyond that date or for any purpose other than this case is prohibited.

**C. Amendments & Verification**

**1. Duty to Supplement**

Each Plaintiff shall remain under a duty to supplement the information provided in the PFS pursuant to Federal Rule of Civil Procedure 26(e) when appropriate.

**2. Verification**

Each completed PFS shall be verified, either (i) with an electronic signature via DocuSign (or another substantially similar platform on which the parties agree), or (ii) with a wet signature, and dated by the Plaintiff(s) or the Plaintiff's representative as if it were interrogatory responses under Federal Rule of Civil Procedure 33. The Requests for Production of Documents in the PFS shall be treated as document requests under Federal Rule of Civil Procedure 34.

**3. Objections**

The questions in the PFS shall be answered without objection, including as to relevance, proportionality, or the form of the question. The only permissible objections shall be as to privilege.

**D. Deficiency and Dispute Resolution Process**

**1. Notice by Defendants of Overdue Plaintiff Fact Sheet**

Any Plaintiff who fails to comply with his or her PFS obligations under this Order may be subject to having his or her claims dismissed. If a Plaintiff has not submitted a verified PFS and/or the required authorizations and documents (the “Required Materials”) by the applicable due dates, the Defendants may send a Notice of Overdue Plaintiff Fact Sheet via Crosslink.

**2. Motion to Dismiss Without Prejudice**

If a Plaintiff fails to submit the Required Materials within 30 days after receipt of the Notice of Overdue Plaintiff Fact Sheet, any Defendant may move the Court for entry of an order dismissing the Plaintiff’s complaint without prejudice. A Plaintiff subject to such motion shall have 14 days from the date of the Defendant’s motion to file a response either: (1) certifying that the Plaintiff has submitted the Required Materials, or (2) opposing the Defendant’s motion for other reasons. If a Plaintiff certifies that he or she has submitted the Required Materials, the Plaintiff’s claims shall not be dismissed (unless the Court finds that the certification is false or incorrect).

**3. Motion to Convert Order of Dismissal without Prejudice to Order of Dismissal with Prejudice**

If the Court dismisses a complaint without prejudice under the previous paragraph, the Defendant may move the Court no earlier than 30 days after the Court’s entry of the order to convert the order to an order of dismissal with prejudice. A Plaintiff subject to such motion shall

have 14 days from the date of the Defendant's motion to file a response either: (1) certifying that the Plaintiff has submitted the Required Materials, or (2) opposing the Defendant's motion for other reasons. If a Plaintiff certifies that he or she has submitted the Required Materials, the Defendant shall withdraw the motion to convert the order of dismissal without prejudice, and shall also submit a stipulated motion to vacate the order of dismissal without prejudice (unless the Court finds that the certification is false or incorrect).

If the Plaintiff serves Defendants' counsel or their designee(s) with the Required Materials prior to the filing of Defendant's motion to convert an order of dismissal without prejudice to an order of dismissal with prejudice, the parties shall submit a stipulated motion to vacate the order of dismissal without prejudice.

**4. Other Plaintiff Fact Sheet Deficiencies**

If any Defendant believes a Plaintiff Fact Sheet is deficient in other respects, the parties shall address such issues pursuant to the appropriate discovery dispute procedures (including meet and confer requirements) under the Local Rules of this District Court, the Chambers Rules of this Court, and any applicable Orders of the Court in this MDL.

**III. SERVICE AND TIMING OF THE PFS AND RELATED MATERIALS**

**A. Cases Currently Pending in This District**

Each Plaintiff in a Member Action that is pending in the Eastern District of Pennsylvania shall have 45 days after the Crosslink platform goes live to serve their Required Materials.

**B. Cases Filed in or Transferred After the Entry of This Order**

Each Plaintiff in a Member Action that is not pending in the Eastern District of Pennsylvania on the date of entry of this Order but which thereafter becomes part of MDL 3094 shall have 45 days from the date that the case becomes part of MDL 3094 or from the date

Defendants are served, whichever is later, to serve their Required Materials. For cases the JPML transfers to the MDL after entry of this Order, a case shall be deemed to be part of the MDL either: (1) on the date the Clerk enters a certified copy of the JPML's Conditional Transfer Order on the docket of this Court, or (2) where transfer is contested, the date of transfer in any subsequent order from the JPML.

**C. Transmission of PFS and Other Documents to Defendants**

Pursuant to the agreement of the parties, all Plaintiff Fact Sheets described in this Order shall be completed electronically and served to Defendants using the Rubris "Crosslink" system. Signed authorizations and responsive documentation shall also be uploaded using Crosslink. Medical, pharmacy, and insurance records shall be produced as searchable PDFs with each facility's or provider's records contained in a separate PDF. Any other documents shall be produced in the format set forth in the Court's forthcoming case management order governing ESI.

Counsel for Plaintiffs are required to establish a Crosslink account. The Crosslink application can be accessed at <https://crosslink.rubris.com>. To request access to Crosslink, Counsel for Plaintiffs must send an email to [GLP1Plaintiffs@rubris.com](mailto:GLP1Plaintiffs@rubris.com) and provide the law firm, name, and email address for the individual who will be the firm user manager. The firm user manager will manage access for all users at the firm. At least one attorney representing the law firm must send or be copied on the email request. Please use the following Email subject: Request for Access to GLP-1 RA MDL PFS. Instructions for establishing a Crosslink account using the Crosslink system should be directed to [GLP1Plaintiffs@rubris.com](mailto:GLP1Plaintiffs@rubris.com). Counsel for Defendants' should direct Crosslink access requests to [GLP1Defense@rubris.com](mailto:GLP1Defense@rubris.com).

Rubris shall maintain a secure, confidential and searchable database available to Plaintiffs, Defendants, and any third-party records vendor retained by the parties to obtain the records

specified in the authorizations from the records custodians. The manner in which each party accesses or utilizes the data and the database shall be strictly confidential and not disclosed in any manner by Rubris. Plaintiffs and Defendants shall each pay one half of the cost of the Rubris/Crosslink PFS system. Uploading to Crosslink in the aforementioned manner shall constitute effective service of the PFS and such records.

**IV. CONFIDENTIALITY**

All medical and financial information disclosed in a PFS and all related documents (including health care records and information) produced pursuant to the PFS or from the authorizations provided therewith shall be deemed confidential and treated as “Confidential Information” as defined in the Court’s forthcoming case management order governing protection of documents.

**V. OTHER DISCOVERY**

This Order is without prejudice to the parties’ rights to serve additional discovery at a later time, to be determined according to this Court’s subsequent orders.

**IT IS SO ORDERED.**

*/s/ Karen Spencer Marston*  
**KAREN SPENCER MARSTON, J.**

**EXHIBIT A**



**UNITED STATES DISTRICT COURT  
EASTERN DISTRICT OF PENNSYLVANIA**

**IN RE: GLUCAGON-LIKE  
PEPTIDE-1 RECEPTOR  
AGONISTS (GLP-1 RAs)  
PRODUCTS LIABILITY**

**MDL 3094**

**PLAINTIFF FACT SHEET**

**PLAINTIFF FACT SHEET**

Each plaintiff alleging injury from the use of a glucagon-like peptide 1 receptor agonist (“GLP-1 RA”) must complete this Plaintiff Fact Sheet (“PFS”). If you are completing this PFS in a representative capacity for someone who has died or who otherwise cannot complete the PFS, please answer as completely as you can for that person.

In completing this PFS, you are under oath and must provide information that is true and correct to the best of your knowledge and recollection, and your answers must be as complete as the information currently reasonably available to you permits. If you cannot recall all of the details requested, please provide as much information as you can. You must supplement your responses if you learn that they are incomplete or incorrect.

The parties, through their counsel, have agreed to limit the scope of the information and documents being requested from plaintiffs at this time to that which is set forth in this PFS.

This PFS is completed pursuant to the Federal Rules of Civil Procedure. Your responses to the PFS shall be treated as answers to interrogatories and subject to the requirements of the Federal Rules of Civil Procedure and the applicable Local Rules. Information provided in response to this PFS will be used only for purposes related to this litigation and is subject to the Protective Order, entered in this MDL as Case Management Order No. 11, and may be disclosed only as permitted by the Protective Order in this litigation.

**I. GENERAL INFORMATION**

- A. Name of person completing this PFS: \_\_\_\_\_
- B. Please state the following for the civil action which you filed:
  - 1. Case Caption: \_\_\_\_\_
  - 2. Case No: \_\_\_\_\_

3. Principal attorney(s) representing you and his/her contact information:

\_\_\_\_\_  
Name

\_\_\_\_\_  
Firm

\_\_\_\_\_  
E-mail Address

C. If you are completing this PFS in a representative capacity, please complete the following:

1. Your name and **Social Security number**:

\_\_\_\_\_

2. Your current address:

\_\_\_\_\_

3. The name of the individual or estate you are representing, and in what capacity you are representing the individual or estate:

\_\_\_\_\_

4. If you were appointed as a representative by a court, state the:

\_\_\_\_\_  
Court

\_\_\_\_\_  
Date of Appointment

5. Your relationship to the plaintiff on whose behalf you are completing this PFS: \_\_\_\_\_

6. If you represent a decedent's estate, state the date and place of the decedent's death:

a. Date of Decedent's Death: \_\_\_\_\_

b. Place of Decedent's Death: \_\_\_\_\_

*The remainder of this Fact Sheet requests information about the person who alleges injury from the use of a GLP-1 RA and/or GLP-1 RA/GIP RA (hereinafter, "GLP-1 RA"). If you are completing this PFS in a representative capacity, please respond to the remaining questions with respect to the person who allegedly used the GLP-1 RA, unless the question instructs you otherwise. Questions using the term "You" refer to the person who allegedly used the GLP-1 RA, unless instructed otherwise. Append additional pages if more space is necessary.*

**II. PERSONAL INFORMATION ABOUT THE GLP-1 RA USER**

A. Full Name: \_\_\_\_\_

B. **Social Security Number** (if not provided above): \_\_\_\_\_

- C. Medicare Beneficiary Identifier (if any): \_\_\_\_\_
- D. Biological sex at birth: \_\_\_\_\_
- E. Maiden name or other names used or by which you have been known, and the date(s) you were known by those other names: \_\_\_\_\_
- F. Current address (or last address, if the person you allege was injured is deceased):  
\_\_\_\_\_
- G. Date of birth: \_\_\_\_\_
- H. Are you currently employed?  Yes  No
- I. If you are currently employed, please provide the following information regarding your current employer:
1. Name of Employer: \_\_\_\_\_
  2. Dates of employment: \_\_\_\_\_
  3. Occupation / Job duties: \_\_\_\_\_
- J. Are you claiming or do you expect to claim that you **lost earnings or impairment of earning capacity** as a result of any injury/condition(s) you contend was/were caused by your use of GLP-1 RAs?  Yes  No
1. If yes:
    - a. State the total amount of time you have lost from work as a result of any injury/condition(s) you claim or believe was/were caused by your use of GLP-1 RAs: \_\_\_\_\_
    - b. Your weekly wage / salary: \_\_\_\_\_
    - c. The amount of income you lost: \_\_\_\_\_
- K. If you are not currently employed, did you leave the last job for a medical reason?  Yes  No
1. If yes, describe why you left your last job: \_\_\_\_\_
- L. Identify each insurance carrier (including government health programs) with whom you have had health insurance coverage beginning five (5) years before your first GLP-1RA prescription at issue in this litigation:

Insurance Co.	Policy No.	Policy Holder	Approx. Dates of Coverage

**III. USE OF GLP-1 RA MEDICATIONS**

A. To the best of your current recollection, identify each and every GLP-1 RA that you have ever been prescribed or used; include medicines prescribed even if you did not end up using them:

Medicine	Check If Ever Prescribed	Check If Ever Taken
Adlyxin® (lixisenatide)		
Bydureon BCise® (exenatide)		
Byetta® (exenatide)		
Compounded dulaglutide		
Compounded semaglutide		
Compounded tirzepatide		
Mounjaro® (tirzepatide)		
Other (specify): _____		
Other semaglutide (other generic manufacturer / supplier)		
Other tirzepatide (other generic manufacturer / supplier)		
Ozempic® (semaglutide)		
Rybelsus® (semaglutide)		
Saxenda® (liraglutide)		
Soliqua® (insulin glargine and lixisenatide)		
Trulicity® (dulaglutide)		
Victoza® (liraglutide)		
Wegovy® (semaglutide)		
Xultophy® (Insulin degludec/liraglutide)		
Zepbound® (tirzepatide)		

B. For each GLP-1 RA identified as having been taken above, please provide the information requested below. You must answer each question separately for each GLP-1 RA you have taken, including separately for compounded and branded products.

1. Medicine: \_\_\_\_\_
2. Are you claiming use of this medicine caused or is related to any injury you are suing for:  Yes  No
3. List the condition(s) for which you used this medicine:  
 Glycemic control for Type 2 Diabetes

- Chronic Weight Management/Obesity
- To reduce risk of major adverse cardiovascular events
- Other weight loss
- Other (specify): \_\_\_\_\_

4. When did you use this medicine?

- a. Date of First Use: \_\_\_\_\_
- b. Weight at the Time of First Use: \_\_\_\_\_
- c. Date of Last Use: \_\_\_\_\_
- d. Weight at the Time of Last Use: \_\_\_\_\_

5. For every dosage taken of this medicine, please provide:

- a. Dose: \_\_\_\_\_
- b. Date you began taking this dose: \_\_\_\_\_
- c. Frequency of use: \_\_\_\_\_
- d. All other start and stop dates for this dose: \_\_\_\_\_
- e. Last date medication taken at this dosage: \_\_\_\_\_

Add Another Dosage

6. Do you still use the medicine?  Yes  No

7. During your use of this medicine, did you use any other GLP-1 RA?  
 Yes  No

a. If yes, please identify the GLP-1 RA(s) used: \_\_\_\_\_

8. Identify the name, affiliation, address, and contact information of each and every healthcare provider (“HCP”) who prescribed this medicine to you:

HCP Name: \_\_\_\_\_

Affiliation/Practice: \_\_\_\_\_

Address: \_\_\_\_\_

Is this provider a telemedicine provider:  Yes  No

Is this provider a medical spa/medspa, wellness clinic, or similar location?  Yes  No

First Date of Prescription(s):

Month \_\_\_\_\_ Year \_\_\_\_\_

Most Recent Date of Prescription(s) :

Month \_\_\_\_\_ Year \_\_\_\_\_

9. Identify the name and address of each and every pharmacy location where you filed a prescription for this medicine.

Pharmacy Name: \_\_\_\_\_

Address: \_\_\_\_\_

Online/Mail Order Pharmacy:  Yes  No

**IV. INJURIES AND CLAIMS**

A. Please identify each and every injury for which you are suing and that you claim was caused or worsened by use of any GLP-1 RA:

Claimed Injury	Check If Injured or Symptom Claimed
Gastroparesis	
Indigestion (Dyspepsia)	
Nausea	
Vomiting	
Constipation	
Decreased Appetite	
Stomach (Abdominal) Pain	
Diarrhea	
Intestinal/Bowel Obstruction/Blockage	
Ileus	
Malnutrition	
Dehydration	
Pulmonary Aspiration	
Pulmonary Embolism	
Deep Vein Thrombosis	
Wernicke encephalopathy/Wernicke-Korsakoff Syndrome	
Cholelithiasis (Gallstones)	
Cholecystitis (Gallbladder Inflammation)	
Gallbladder Removal	
Acute Kidney Injury	
Pancreatitis (Inflammation of Pancreas)	
Death	
Other (Specify): _____	

B. For each claimed injury, please provide the information requested below. You must answer each question separately for each injury you allege.

1. Injury: \_\_\_\_\_
2. Which medication(s) do you claim caused or worsened your [INJURY]?

GLP-1 RA Medication Used	Do you claim the product caused your [INJURY]?	Do you claim this product worsened your [INJURY]?
[PRODUCT #1]	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/> No <input type="checkbox"/> Yes
[PRODUCT #2]	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/> No <input type="checkbox"/> Yes
[PRODUCT #3]	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/> No <input type="checkbox"/> Yes
[PRODUCT #4]	<input type="checkbox"/> No <input type="checkbox"/> Yes	<input type="checkbox"/> No <input type="checkbox"/> Yes

3. Describe when you experienced [INJURY]:
- a. When did you first experience or otherwise learn of your [INJURY]? \_\_\_\_\_
  - b. Has your [INJURY] resolved?  Yes  No  
If so, when: \_\_\_\_\_
  - c. If not, when did you most recently experience [INJURY]?  
\_\_\_\_\_
  - d. How often did your experience your [INJURY]?
    - One time only
    - Daily
    - Weekly
    - Monthly
    - Other (explain): \_\_\_\_\_
4. How do you describe the severity of your [INJURY]?
- Mild
  - Moderate
  - Severe
- a. Has the severity your [INJURY] changed over time?  Yes  No  
If so, when did they change? \_\_\_\_\_  
How did they change? \_\_\_\_\_
5. For each medication you claim worsened your [INJURY], provide the following information:
- a. Medication: \_\_\_\_\_

b. With respect to your claim that [PRODUCT #1] worsened your [INJURY], when did your [INJURY] worsen? \_\_\_\_\_

c. With respect to your claim that [PRODUCT #1] worsened your [INJURY], describe how your [INJURY] got worse?

\_\_\_\_\_

\_\_\_\_\_

d. What was the severity of your [INJURY] before you first used [PRODUCT #1]?

- Mild
- Moderate
- Severe

e. What was the severity of your [INJURY] after your use of [PRODUCT #1]?

- Mild
- Moderate
- Severe

6. Has an HCP told you that you have [INJURY] or diagnosed you with [INJURY]?  Yes  No

a. If Yes, please identify following information:

HCP Name: \_\_\_\_\_

Affiliation/Practice: \_\_\_\_\_

Address: \_\_\_\_\_

Date first contacted: \_\_\_\_\_

Date of diagnosis: \_\_\_\_\_

7. Has an HCP ever provided treatment for [INJURY]?  Yes  No

a. If Yes, identify each healthcare provider from whom you have received treatment for your injury:

HCP Name: \_\_\_\_\_

Affiliation/Practice: \_\_\_\_\_

Address: \_\_\_\_\_

b. Describe the treatment and dates received (e.g., medication, surgery)

\_\_\_\_\_

Add Another Treatment for [INJURY]



8. Were you ever admitted to the hospital or treated at the hospital for [INJURY]?  Yes  No

If yes, provide the following information for each hospital visit:

Admission Date: Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

Discharge Date: Month \_\_\_\_\_ Day \_\_\_\_\_ Year \_\_\_\_\_

Hospital: \_\_\_\_\_

Address: \_\_\_\_\_

9. Has any HCP told you that the [INJURY] was caused by your use of GLP-1 RAs?  Yes  No  Unsure

If yes, for [INJURY], state who told you and the date and form of that communication: \_\_\_\_\_

10. Please identify all diagnostic tests that you have undergone to evaluate and/or diagnose your alleged [INJURY] (complete all that apply).

Diagnostic Test	Have you undergone this test to evaluate/diagnose your alleged [INJURY]?	Date	Location	Check if you have copies of the results of this test in your possession.
Abdominal CT				
Abdominal MRI				
Abdominal Ultrasound				
Abdominal X-Ray				
Colonoscopy				
Gastric Emptying Study				
Upper GI Endoscopy				
Other (Specify)				

C. Are you claiming that emotional distress or a psychiatric injury or condition was caused or worsened as a result of your use of [PRODUCT #1], beyond the pain and suffering, emotional distress and mental anguish from the underlying claimed physical injury?

Yes  No

1. If Yes, describe the emotional distress or a psychiatric injury or condition you attribute to your use of the GLP-1 RA(s) identified above:  
 \_\_\_\_\_  
 \_\_\_\_\_  
 \_\_\_\_\_
  
2. For each identified psychiatric injury or condition, please separately provide the following information:
  - a. State whether you were treated for the condition(s) prior to your use of the GLP-1 RA:  Yes  No
  - b. State the name and address of each physician, therapist, mental healthcare provider, or other healthcare provider from whom you have received treatment for such condition(s) \_\_\_\_\_  
 \_\_\_\_\_
  - c. Dates on which treatment was received: \_\_\_\_\_
  
3. If you are claiming worsened emotional distress or psychiatric injury or condition of the injury, state the date of original diagnosis.  
 \_\_\_\_\_

**V. MEDICAL / HEALTH BACKGROUND**

- A. Height: \_\_\_\_\_
- B. Current weight: \_\_\_\_\_
- C. Highest weight: \_\_\_\_\_ Date: \_\_\_\_\_
- D. Name of current primary care physician or healthcare provider:  
 \_\_\_\_\_
- E. Address of current primary care physician or healthcare provider:  
 \_\_\_\_\_
- F. Have you ever been diagnosed with Type 2 diabetes?  Yes  No
  1. If Yes, please state date of diagnosis and diagnosing healthcare provider:  
 \_\_\_\_\_
  2. If Yes, please provide all medications ever taken for diabetes treatment and dates used: \_\_\_\_\_
  3. If Yes, please identify all HCPs (including primary care, endocrinologists, urgent care facilities or hospitals that have ever diagnosed or treated your Type 2 diabetes or any complications related to your Type2 diabetes) and the dates of diagnosis or treatment: \_\_\_\_\_  
 \_\_\_\_\_

G. Have you ever consulted with an endocrinologist, including for matters related to diabetes or prediabetes or weight?  No  Yes

1. If Yes, Name and address of most recent endocrinologist: \_\_\_\_\_  
\_\_\_\_\_

H. Have you ever discussed bariatric surgery with a healthcare provider?

No  Yes

1. If Yes, have you ever had bariatric surgery?  No  Yes

a. If yes, please provide date, facility where the procedure occurred, and the healthcare provider who performed the surgery:

\_\_\_\_\_  
\_\_\_\_\_

2. Have you used any GLP-1 RA for overweight or obesity indications, or in order to lose weight?  No  Yes

a. If yes, what other weight loss methods or medicines (not including a GLP-1 RA) have you tried?

\_\_\_\_\_

b. Excluding pregnancy, have you ever intentionally lost more than 20 pounds without weight loss surgery or medicine?  Yes  No

c. Excluding pregnancy, have you ever unintentionally lost more than 20 pounds without weight loss surgery or medicine?  Yes  No

I. Identify each of your **HCPs** (including primary care, endocrinologist, and anyone involved in treating the condition for which you were prescribed GLP-1 RA and the injuries you allege were caused by the GLP-1 RA), from five (5) years prior to your first GLP-1 RA prescription to present:

\_\_\_\_\_  
Name

\_\_\_\_\_  
Approximate Dates

\_\_\_\_\_  
Address

Add Another HCP

J. Identify each hospital, clinic, or healthcare facility where you have received **inpatient treatment**, from five (5) years prior to your first GLP-1 RA prescription to present:

\_\_\_\_\_  
Name

\_\_\_\_\_  
Address

\_\_\_\_\_  
Dates of Admission

\_\_\_\_\_  
Reason for Admission

Add Another Inpatient Facility

- K. Identify each hospital, clinic, or healthcare facility where you have received **outpatient treatment** (including treatment in an emergency room), from five (5) years prior to your first GLP-1 RA prescription to present:

\_\_\_\_\_  
Name

\_\_\_\_\_  
Address

\_\_\_\_\_  
Dates of Treatment

Add Another Date of Treatment at Same Outpatient Facility

\_\_\_\_\_  
Reason for Treatment

Add Another Outpatient Facility

- L. Identify on the chart below each **prescription medication** (excluding antibiotics and antivirals) you have taken in the five (5) years prior to your first treatment with any GLP-1 RA up to the present:

Medication	Reason Prescribed	Dates of Use	Prescriber	Dispensing Pharmacy or Where Purchased

- M. Identify on the chart below each **Over-the-Counter (“OTC”) medication, including vitamins, herbal remedies, and supplements**, you have routinely taken in the five (5) years prior to your first treatment with any GLP-1 RA up to the present:

Medication	Reason Prescribed	Dates of Use	Prescriber	Dispensing Pharmacy or Where Purchased

N. To the best of your knowledge, have you ever experienced, or been told by a physician or other healthcare provider, that you presently have, may have, or had any of the following at any time in your life (check all that apply)?

\*Responses to conditions listed with an asterisk (“\*\*”) are designated as Highly Confidential under the Protective Order.

<b>Alcoholism within five years of injury claimed in Section IV*</b>		(PAD), arrythmia, coronary artery disease (CAD), and/or peripheral vascular disease (PVD))	
<b>Disordered Eating Diagnosis* (e.g. anorexia, bulimia, binge eating)</b>		Hernia (including hiatal)	
<b>Gastrointestinal complications from alcoholism* (e.g., liver damage, gastritis, reflux, pancreatitis, etc.)</b>		High cholesterol and/or triglycerides within five years of injury claimed in Section IV	
<b>Gastrointestinal complications from opioid use disorder*</b>		Hypothyroidism	
Autoimmune disease		Ileus	
Cancer		Intestinal obstruction/blockages	
Celiac disease		Inflammatory bowel disease	
Chronic constipation		Intussusception	
Chronic kidney disease		Irritable bowel disease	
Cyclic vomiting syndrome		Malnutrition/malabsorption	
Cystic fibrosis		Metabolic syndrome	
Diabetes, Type 1		Multiple sclerosis	
Diabetes, Type 2		Pancreatitis	
Diverticulitis		Parkinson’s Disease	
GI Issues (i.e. Dyspepsia, dysphagia, reflux disorder (GERD) and/or indigestion)		Peptic ulcer disease	
Ehlers-Danlos Syndrome		Peripheral neuropathy	
End Stage Renal Disease		Prediabetes	
Esophageal injury		Pulmonary aspiration	
Gallbladder injury/inflammation		Scleroderma	
Gallstones		Severe gastrointestinal disease	
Gastroparesis		Severe or persistent nausea, vomiting or diarrhea (> 1 month)	
Heart disease (i.e. congestive heart failure, peripheral arterial disease)		Stroke or Transient Ischemic Attack	
		Treatment for weight management or obesity	
		Vagus nerve injury	
		Volvulus	

O. Within five years of injury claimed in Section IV, have you been diagnosed or treated for any of the following mental health conditions: anxiety, bipolar disorder, depression, schizophrenia and/or somatoform disorder?  No  Yes

1. If yes, please identify which conditions you have been diagnosed with

\_\_\_\_\_

- P. Have you been prescribed medication to lower cholesterol or triglycerides (e.g. statins, Lipitor)?  No  Yes
- Q. For each condition checked above, please state the condition(s), the date of onset, any treatment received (including medication prescribed and/or taken), the name of the healthcare provider or other person who made the diagnosis or informed you of the condition(s), and their address.
1. Condition(s): \_\_\_\_\_
  2. Onset date: \_\_\_\_\_
  3. Treatments received, including Medications prescribed to treat or manage:  
\_\_\_\_\_
  4. Has the condition resolved?  Yes  No  
a. If so, when:
  5. Name and address of healthcare provider or other person:  
\_\_\_\_\_
- R. Based on your current recollection and understanding, have you had any of the following medical tests or procedures?

Medical Test or Procedure	Yes	Approximate Date	Doctor or Hospital/Facility
Abdominal ultrasound (other than pregnancy-related)			
Abdominal irradiation			
Abdominal surgery			
Cesarean Section			
Barium or Air Enema			
Barium Swallow / Upper GI Series			
Colonoscopy			
Computerized tomography (CT) scan of abdomen			
Coolsculpting			
Fundoplication (surgery for treatment of reflux)			
Gastric emptying breath test			
Gastric emptying scintigraphy (also called gastric emptying scan or gastric emptying test)			
GI endoscopy			
Isotope breath test			
Abdominal lipoplasty, liposuction, or suction lipectomy			
Magnetic resonance imaging (MRI) of abdomen			
Abdominal or Gastrointestinal surgery within five years of injury listed in Section IV (specify):			

Medical Test or Procedure	Yes	Approximate Date	Doctor or Hospital/ Facility
Partial gastric resection			
Vagotomy			
Whipple procedure			
Wireless motility capsule (sometimes called a SmartPill)			
X-ray of any part of the abdomen			
Other abdominal fat reducing procedure (specify):			
Pelvic surgery with or for complications within five years of injury listed in Section IV (specify):			

S. If you are claiming an injury in Section IV related to pulmonary aspiration, based on your current recollection and understanding, please identify all surgeries requiring general anesthesia not identified above.

Medical Test or Procedure	Date	Doctor or Hospital / Facility

**VI. DOCUMENTS AND THINGS**

Please check “Yes” or “No” as appropriate below to indicate whether you, your parents, guardians or spouse, or your lawyers currently possess documents described by the various categories listed.

Document Request No.	Category/Description	Yes	No
1.	For [PRODUCTS], pharmacy records substantiating that you filled a prescription for that GLP-1 RA prior to the date of the alleged injury(ies)	<input type="checkbox"/>	<input type="checkbox"/>
2.	Regarding the injury(ies)/condition(s) you contend were caused by GLP-1 RA(s), medical records evidencing or otherwise reflecting the injury(ies)/condition(s)	<input type="checkbox"/>	<input type="checkbox"/>
3.	<u>If you allege gastroparesis as an injury, medical records</u> documenting proof of diagnosis, including any confirmatory testing	<input type="checkbox"/>	<input type="checkbox"/>
4.	A copy of all prescriptions for [PRODUCTS]	<input type="checkbox"/>	<input type="checkbox"/>

5.	Any unused GLP-1 RAs, including pens, containers, boxes, packaging, and/or labeling	<input type="checkbox"/>	<input type="checkbox"/>
6.	Receipts for [PRODUCTS]	<input type="checkbox"/>	<input type="checkbox"/>
7.	Photographs of medicine containers, bottles, pens, vials or packaging related to GLP-1 RAs	<input type="checkbox"/>	<input type="checkbox"/>
8.	Any other medical records that show the period during which you have taken [PRODUCTS], the dosage of the [PRODUCTS] and/or the frequency with which you took [PRODUCTS]	<input type="checkbox"/>	<input type="checkbox"/>
9.	Medical records, communications with medical providers and diagnostic imaging referring or relating to claims, information contained in this Plaintiff Fact Sheet, and pharmacy records for prescriptions filled (regardless of whether they were for GLP-1 RAs)	<input type="checkbox"/>	<input type="checkbox"/>
10.	Documents relating to your insurance coverage that is/are applicable to the illness, injury, or medical condition that forms the basis of your complaint, including any application to any insurer for coverage, whether insurance was obtained or not	<input type="checkbox"/>	<input type="checkbox"/>
11.	Any documents, communications (excluding those to or from your attorney), notes, summaries, diaries, recordings, videos, tapes, writing, social media posts, or other written or electronic material that describes, discusses, or relates to your use of GLP-1 RAs, your lawsuit, and/or any injury(ies)/condition(s) for which you seek recovery in this lawsuit.	<input type="checkbox"/>	<input type="checkbox"/>
12.	All materials or items that were referenced or referred to as part of completing this Fact Sheet	<input type="checkbox"/>	<input type="checkbox"/>
13.	Copies of death certificate of decedent (if applicable), letters testamentary, letters of administration, powers of attorney, guardianship or guardian <i>ad litem</i> orders or other documents relating to your status as plaintiff if you are suing on behalf of another individual	<input type="checkbox"/>	<input type="checkbox"/>



For each category of document for which you have indicated “yes,” produce a copy of all the documents in the manner set forth in the CMO governing Plaintiffs Fact Sheets.

If you have indicated “no,” for Document Request No. 1-2 in the chart above: within 90 days of initial service of your Plaintiff Fact Sheet, you must obtain copies of records sufficient to meet this requirement and produce those records in the manner set forth in the CMO governing Plaintiffs Fact Sheets.

To the extent these materials are currently in the possession, custody or control of you, your parents, guardians or spouse, or your lawyers, please produce.

In addition to the documents above, please provide signed blank authorizations in the forms attached as Exhibits B-Q. Please only fill out the highlighted portions asking for your (patient or personal representative) name, date of birth, and social security number. Please sign and date and have a witness sign/date. Do not fill out the un-highlighted portions requesting the name or address of the healthcare provider or the representative to whom the records should be released. You need to provide a signed Authorization for the Release of Mental Health Records (Exhibit C) only if you are claiming damages for psychological injury or mental or emotional distress. You need to provide a signed Authorization to Disclose Employment Information (Exhibit D) only if you are making a claim for lost wages.

**VII. DECLARATION**

I declare under penalty of perjury that all of the information provided in this Plaintiff Fact Sheet is true and correct to the best of my knowledge, recollection, information and belief.

\_\_\_\_\_  
Dated

\_\_\_\_\_  
Signature